SPI-B Activates Transcription via a Unique Proline, Serine, and Threonine Domain and Exhibits DNA Binding Affinity Differences from PU.1*

Sridhar Rao‡§, Amy Matsumura¶, Jung Yoon% and M. Celeste Simon†**

From the ‡Department of Pathology, ¶Howard Hughes Medical Institute, and §Departments of Medicine and Molecular Genetics and Cell Biology, the University of Chicago, Chicago, Illinois 60637

SPI-B is a B lymphocyte-specific Ets transcription factor that shares a high degree of similarity with PU.1/SPI-1. In direct contrast to PU.1−/− mice that die in utero and lack monocytes, neutrophils, B cells, and T cells, SPI-B−/− mice are viable and exhibit a severe B cell proliferation defect. Since PU.1 is expressed at wild type levels in Spi-B−/− B cells, the mutant mice provide genetic evidence that SPI-B and PU.1 have at least some non-redundant roles in B lymphocytes. To begin to understand the molecular basis for these defects, delineated functional domains of SPI-B for comparison to those of PU.1. By using a heterologous co-transfection system, we identified two independent transactivation domains in the N terminus of SPI-B. Interestingly, only one of these domains (amino acids 31–61), a proline-serine/threonine-rich region, unique among Ets proteins, is necessary for transactivation of the immunoglobulin λ light chain enhancer. This transactivation motif is in marked contrast to PU.1, which contains acidic and glutamine-rich domains. In addition, we describe a functional PU.1 site within the c-FES promoter which SPI-B fails to bind efficiently and transactivate. Finally, we show that SPI-B interacts with the PU.1 cofactors Pip, TBP, c-Jun and with lower affinity to nuclear factor interleukin-6β and retinoblastoma. Taken together, these data suggest that SPI-B binds DNA with a different affinity for certain sites than PU.1 and harbors different transactivation domains. We conclude that SPI-B may activate unique target genes in B lymphocytes and interact with unique, although currently unidentified, cofactors.

Hematopoiesis represents the coordinated development of all blood cell lineages (granulocytes, monocytes, lymphocytes, erythrocytes, and platelets), which arise from a self-renewing, pluripotent stem cell. This complex developmental process is guided by interactions between extracellular signals, cell-surface receptors, cell-cell interactions, and the regulation of gene expression by transcription factors (reviewed in Refs. 1 and 2). Transcription factors play a crucial role in hematopoiesis due to their ability to regulate gene expression controlling the eventual differentiation and development of distinct cell types.

One family of transcription factors thought to play a pivotal role in hematopoiesis is the Ets DNA-binding proteins. This family of transcription factors consists of approximately 30 different proteins that bear a high degree of similarity to the founding member, Ets-1. Ets proteins are monomeric transcription factors that bind to the purine-rich element of GGA(A/T) through their Ets domain (3–6). Based upon differences within the Ets and other domains, Ets proteins can be divided into a series of subfamilies consisting of the Ets-1, PU.1, Elf-1, Fli-1, and GABPs groups. The PU.1 subgroup consists of PU.1/SPI-1 and SPI-B and represents the most divergent members of the Ets family due to many differences in the Ets domain (40% similarity to Ets-1). In contrast to other Ets proteins, both PU.1 and SPI-B can bind the non-canonical DNA sequence GCAAGA (7).

In addition to having a distinct DNA binding domain compared with other Ets family members, PU.1 possesses several protein motifs unique among Ets proteins (Fig. 1). PU.1 has a C-terminal Ets domain that is involved in both DNA binding as well as protein-protein interactions involving AP-1 family members (8, 9), NF-IL6β (C/EBPβ) (10), and other Ets proteins (11, 12). Immediately adjacent to the Ets domain is a proline-, glutamic acid-, serine-, and threonine-rich (PEST) region, which is involved in protein-protein interactions with the lymphoid-specific co-activator Pip/IRF4/NF-EM5 and other IFR proteins (13, 14), but does not destabilize protein as other PEST sequences do (15). The PU.1-Pip interaction is crucial for the transcription of immunoglobulin light chain loci (13) and CD20 (16) and requires PU.1 binding to DNA with subsequent recruitment of Pip via a phosphorylated serine residue (Ser-148) in the PEST region (17, 18). At the N terminus of PU.1 resides a series of three independent transcriptional activation domains, including two acidic subdomains and one glutamine-rich domain (19). In addition to activating transcription, the N terminus of the protein has been shown to interact with Rb and TBP (20).

In contrast to PU.1, very little is known about the functional domains of SPI-B (Fig. 1). The two proteins are 50% similar overall, with the N terminus of SPI-B being highly diverged from PU.1 (20% similarity) but presumed to contain the

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Fellow of the Medical Scientist Training Program at the University of Chicago.

** Supported by National Institutes of Health Grant HL5-2094 and a Howard Hughes Medical Institute Investigator. To whom correspondence should be addressed: Howard Hughes Medical Institute, University of Chicago, 5841 S. Maryland Ave., MC 1028, Chicago, IL 60637. Tel.: 773-702-4721; Fax: 773-702-2681; E-mail: csimon@medicine.bsd.uchicago.edu.

† The abbreviations used are: NF-IL6β, nuclear factor interleukin-6β; Rb, retinoblastoma protein; PEST, proline-, glutamic acid-, serine-, and threonine-rich, aa, amino acid(s); B4, tetramerized AB element; TK, herpes simplex virus thymidine kinase promoter; GH, human growth hormone protein; PGR, polymerase chain reaction; CMV, cytomegalovirus; GAL4, GAL4 DNA binding domain; EMSA, electrophoretic mobility shift assay; GST, glutathione S-transferase protein; IVT, in vitro transcribed and translated protein; HA, the hemagglutinin epitope YPYDVPDYA; PAGE, polyacrylamide gel electrophoresis.
and/or (ii) bind different cofactors. To distinguish between these two possibilities, we attempt to elucidate differences between SPI-B and PU.1 which may alter their transcriptional activity. These studies reveal that SPI-B contains two N-terminal activation domains which are highly divergent from PU.1. In addition, the affinity of SPI-B for certain DNA sites appears to be different from PU.1, affecting the ability of SPI-B to transactivate the c-FES promoter, a known PU.1 target gene. Finally, SPI-B is shown to interact with Pip as well as other proteins in a manner similar to PU.1, suggesting that these interactions are critical for the proper function of the PU.1/SPI-B Ets subfamily but that interactions with other cofactors may contribute to differences in their ability to activate target genes.

Experimental Procedures

Plasmids and Site-directed Mutagenesis—A tetrameric λ_{l-4} enhancer element (referred to as the AB site) (13) was subcloned immediately upstream of a TK (2) promoter in the pTKGH plasmid (Nichols Institute) to form the reporter construct B4TKGH. The 450-base pair promoter fragment from the human c-FES gene (44) was subcloned into the promoterless pG5GH plasmid (Nichols Institute) to form the reporter construct c-FES GH. The pGAL4GH (45) reporter and the Pip-CMV vector (23) have been previously described. The human SPI-B (21) and murine PU.1 (25) cDNA have also been previously reported. Of note, the human SPI-B is 96% similar to the murine form, with only conservative differences in the Ets domain.

All plasmids for cDNA expression in mammalian cells used the CMV promoter-based pcDNA3 vector (Invitrogen). Constructs were generated by PCR and confirmed by sequencing. Deletion mutants are named based upon the amino acids that are missing from the protein. Hemagglutinin (HA) epitope-tagged cDNAs were generated by cloning PCR-generated fragments into the previously described vector pcDNA3-HA (18). SPI-B/PU.1 Ets and PU.1/SPI-B Ets contain XhoI and HindIII linkers between domains which insert two in-frame codons (LG and KL, respectively). ΔPEST (aa 107–165), Δ31–62, Δ31–106, Δ64–106, ΔEts (aa 166–257), and Δ257–262 contain an internal XhoI site within the deleted region.

GAL4 fusion proteins were constructed by inserting PCR-generated fragments of SPI-B into the pGAL4 vector (45) that contains the DNA binding domain of the GAL4 protein (aa 1–147) followed by a multiple cloning site and in-frame stop codons. Point mutations were introduced by overlapping PCR mutagenesis (46). The mutations are named by the normal amino acid, position, and the new amino acid.

Cells, Transfections, and Reporter Assays—Cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, 100 units of penicillin, and 100 μg of streptomycin. NIH 3T3 fibroblasts were transfected with Lipofectin (Life Technologies, Inc.) according to the manufacturer's protocol. For co-transfection experiments, 2 μg of reporter plasmid and 2 μg of a β-galactosidase expressing plasmid (pMSVβgal) were used. Transfections using the B4TKGH and c-FES GH reporters utilized 20 μg of expression plasmid; 8 μg of expression plasmid were used for the transfections with the GAL4GH reporter. 48 h after transfections, supernatants were collected for human growth hormone assay using a commercially available radioimmunoassay (Nichols Institute). Transfection efficiencies were measured by β-galactosidase activity in cell extracts as described previously (47).

Cos-7 cells were transfected with Lipofectin and 20 μg of expression plasmid. Nuclear extracts were prepared 48 h after transfection using the method of Andrews and Faller (48).

In Vitro Transcription and Translation—[35S]Methionine incorporated IVE proteins were generated using a commercially available TNT-coupled rabbit reticulocyte lysate kit (Promega). Proteins were resolved by SDS-PAGE and quantitated by PhosphorImager analysis (Molecular Dynamics).

Electrophoretic Mobility Shift Assays—Binding reactions were performed at room temperature for 30 min and contained equimolar amounts of IVE protein or 10 μg of nuclear extracts, 10 mM Tris, 1 mM EDTA, 1 mM dithiothreitol, 75 mM KCl, 4% Ficoll, 12.5 mg/ml poly(dI-dC) (Amersham Pharmacia Biotech), and 5 × 10^6 cpm/ml of [32P]-labeled double-stranded oligonucleotide probe. Protein-DNA complexes were resolved on a 6% (19:1) acrylamide:bisacrylamide (Bio-Rad), 0.5% TBE gel at 200 V for 4.5 h, dried, and subjected to autoradiography.

The following double-stranded synthetic oligonucleotides were used

---

FIG. 1. Important functional domains of PU.1 and SPI-B for DNA binding, protein-protein interactions, and transactivation. Critical phosphorylation sites in the two proteins are also shown. * indicates this domain is weakly acidic.
**RESULTS**

Identification of Independent Transactivation Domains—To identify regions of the SPI-B protein that could function as independent transactivation domains, portions of the SPI-B cDNA were fused in frame to the C terminus of the GAL4 DNA binding domain and tested for their ability to transactivate five linked copies of the GAL4 DNA-binding site upstream of a minimal TK promoter and the human growth hormone cDNA (pGAL4GH) when co-transfected into NIH 3T3 cells (Fig. 2A).

As demonstrated in Fig. 2A, the PEST region of SPI-B exhibited no transactivation potential (GAL4/PEST), but the N-terminal 108 amino acids (aa, GAL4-(1–108)) potently activated the expression of the pGAL4GH reporter. C-terminal deletions within this region revealed that even the very N-terminal 30 aa (GAL4-(1–31)) could function as a transcriptional activator.

Western Blot—Results were subjected to Western blot analysis using standard techniques and probed with an anti-HA antibody (Babco).

**FIG. 2.** A, 8 μg of expression plasmid (pCDNA3 based) encoding GAL4/SPI-B fusion proteins were transiently co-transfected with 2 μg of the pGAL4GH reporter and 2 μg of the pMSVβ gal reference plasmid into NIH 3T3 cells. Media and cells were harvested 48 h after transfection and assayed for growth hormone activity. Data are expressed as fold induction (mean ± S.E. of four independent experiments) normalized to the pCDNA3 expression plasmid. B, EMSAs were performed to ensure that all GAL4 fusion proteins were capable of binding DNA using 10 μg of nuclear extracts from COS cells transiently transfected with 20 μg of the expression plasmids shown in A and a radiolabeled double-stranded oligonucleotide containing the consensus GAL4-binding site.
unable to activate transcription. The small stretch of aa contained in the GAL4-(31–61) was able to transactivate the reporter, thereby localizing two independent transactivation domains of SPI-B to aa 1–31 and aa 31–61.

To delineate further the domain contained between aa 31–61 (which conferred transcripational activity at the Aβ site, see below), a series of smaller fusion proteins were generated. As demonstrated in Fig. 2A, GAL4-(31–51) and GAL4-(41–61) still functioned as transcriptional activators, and in fact only 10 aa (GAL4-(41–51)) retained some transactivation potential even though the flanking aa (GAL4-(31–41) and GAL4-(52–62)) did not. However, due to the strong potential exhibited by GAL4-(41–61) over GAL4-(41–51), it appears that the full transcriptional activation domain resides between aa 41 and 61. To ensure that all constructs were stably expressed and capable of binding to the GAL4 DNA element, nuclear extracts were prepared from COS cells transfected with all constructs shown in Fig. 2A and assayed for their ability to bind DNA in an electrophoretic mobility shift assay (EMSA lanes 2–14, Fig. 2B).

Based upon the GAL4 fusion protein analyses, it appears that SPI-B contains two independent transcriptional activation domains. The N-terminal domain (aa 1–31) has a calculated pI of 3.8, making it an acidic domain, similar to a motif found in PU.1 (19) and other Ets proteins (49). However, aa 41–61 most resemble a proline-, serine-, and Threonine (PST)-rich domain since they comprise almost 40% of the amino acids in this region, although it also has some acidic characteristics. PST activation domains have also been identified in GATA factors (45) as well as the homeodomain protein Pax6 (50). Interestingly, computer-based alignment of the PST activation domain of SPI-B yielded no similarity with PU.1 or any other Ets family member (data not shown).

**Transcriptional Activity at the Aβ Enhancer**—It has previously been demonstrated that PU.1 or SPI-B in conjunction with the lymphoid-specific co-activator Pip (13) effectively transactivates a DNA element from the λ enhancer that requires an intact PST sequence (14). However, we determined that APEST was poorly expressed in 3T3 cells, making it difficult to interpret these results (Fig. 3D). As expected, deletion of the Ets domain, which blocks the ability to bind DNA, completely abolished transactivation. Finally, deletion of the very C terminus of SPI-B (Δ257–262), which is not conserved with PU.1, did not significantly alter transactivation from the full-length SPI-B.

To confirm the ability of these SPI-B plasmids to be expressed in mammalian cells, nuclear extracts were prepared from COS cells transfected with each of the above constructs and tested for their ability to bind to a single copy of the Aβ DNA site by EMSA. As demonstrated in Fig. 3B (lanes 2–13), all constructs, except for the Ets deletion mutant (Δ166–256, lane 12), produced a protein-DNA complex not observed in COS cells transfected with empty expression vector (pCDNA3, lane 2), and these constructs migrated more rapidly than the full-length SPI-B. All mutant proteins (except for APEST and ΔEts) were found to interact equivalently with Pip using in vitro transcribed and translated (IVT) plasmids and EMSA (Fig. 3C). Finally, all constructs that failed to transactivate the Aβ reporter element were assayed for stable expression in 3T3 cells by HA epitope tagging (Fig. 3D, lanes 2–10). All proteins (with the exception of ΔPEST) were found to be expressed at least as well as the positive control PU.1 protein (Fig. 3D). Of note, HA Δ31–61, which defines the minimal domain required for transactivation of the Aβ reporter element, was expressed at levels identical to HA SPI-B (Fig. 3D, lanes 3 and 6). Thus, SPI-B seems to require not only its PST and Ets domains for transactivation of the λ enhancer, but also a small number of amino acids (31–61) in its N terminus which corresponds to the PST activation domain.

**Importance of Specific Amino Acids for Transactivation Potential of SPI-B**—To identify important residues of SPI-B required for interactions with Pip, DNA, and other factors, a series of non-conservative mutations in SPI-B were created by site-directed mutagenesis. One important residue in the PST domain of PU.1 is Ser-148, whose phosphorylation by casein kinase II is critical for proper recruitment of Pip and transactivation of the λ enhancer (13, 14, 17, 18). The analogous residue in SPI-B (Ser-144) was mutated to alanine to test whether phosphorylation of this residue is also critical for the SPI-B-Pip interaction. Much like the PU.1 S148A construct, the SPI-B S144A protein reduced the transactivation from the wild type protein by approximately 2-fold (Fig. 4A). However, this transactivation is still higher than when the entire PST region of SPI-B is deleted (ΔPEST, Fig. 3A). This implies that there may be contacts other than Ser-144/Ser-148 made between SPI-B or PU.1 with Pip that are important for transactivation in this system.

Next, the importance of a specific amino acid in SPI-B for contact with DNA and proper transactivation of the Aβ element was tested by mutating Lys-242 to glycine. Based on the co-crystal data of the Ets domain of PU.1 with DNA (51), this mutation in the Ets domain of SPI-B should abolish DNA binding by preventing DNA bending toward the recognition helix. As demonstrated (Fig. 4B), the K242G mutation completely abolishes transactivation at the λ enhancer, implying that DNA binding is prevented (see below). Importantly, K242G is expressed at wild type levels (see Fig. 3D).

Further analysis of important phosphorylation events was performed by the creation of two separate point mutations...
within the PST domain that have been shown to affect SPI-B or PU.1 function. To test the importance of the interaction of SPI-B with Rb, Thr-56 was mutated to alanine to block its phosphorylation by ERK1, thereby allowing Rb to interact with SPI-B constitutively (24). This mutation had no effect on transactivation (Fig. 4A), implying that this amino acid does not play a role in the transcriptional activation of SPI-B at the λB site.

Finally, mutation of two phosphorylation sites in the N terminus of PU.1 (Ser-41 and Ser-45) have been shown to inhibit macrophage proliferation in vitro (52). A similar phosphorylation site in SPI-B (S37), when mutated to alanine, caused no change in transactivation. All proteins were expressed in 3T3 cells, based on Western blot analysis (Fig. 3D, lanes 2, 3, 11, and 12) and bound DNA (except K242G, lane 7) in EMSAs (Fig. 4B, lanes 2–9). Single mutations of all other possible phosphorylation sites to alanine between aa 31 and 61 (Ser-32, Ser-33, Tyr-34, Ser-43, Thr-48, and Tyr-58) of SPI-B showed only minor changes in transcriptional activity at the λB site.

FIG. 3. A, 10 μg of expression plasmids (pCDNA3 based) encoding deletion mutant of SPI-B plus 10 μg of the Pip CMV expression plasmid were transiently co-transfected into NIH 3T3 cells with 2 μg of the B4TKGH reporter and pMSVβgal reference plasmid. 48 h after transfection cell media and cell extracts were prepared and assayed for growth hormone activity. The data are reported as fold induction (mean ± S.E. of four independent experiments) over the pCDNA3 alone. B, to confirm that all deletion mutants were still capable of binding DNA, 10 μg of nuclear extracts from COS cells transiently transfected with 20 μg of each expression plasmid was assayed for binding activity by EMSA using a double-stranded oligonucleotide probe containing the PU.1/Pip site from the λB site. C, to confirm that all deletion mutants were still capable of binding Pip, equimolar amounts of IVT proteins were used in an EMSA with an excess of Pip and a probe containing the PU.1/Pip site from the λB site as in B. WT, wild type. D, to assay directly steady-state protein levels, HA epitope-tagged versions of the indicated constructs were tested for expression in transiently transfected 3T3 cells by Western blot analysis, illustrating that all constructs (except ΔPEST) were expressed at least as well as PU.1.
To investigate further the interactions between SPI-B and Pip at the \( \lambda_B \) DNA element, IVT proteins were generated, and equimolar amounts were used in an EMSA assay at the \( \lambda_B \) site to test their ability to bind DNA and interact with Pip. Pip has previously been shown to bind very poorly to this site and requires recruitment via PU.1 (13, 14, 18). As shown in Fig. 4C, PU.1 efficiently binds to this DNA site (lane 2) and recruits Pip (lane 3) to form a ternary PU.1-Pip-DNA complex that migrates more slowly. A S148A mutation in PU.1 greatly reduces the recruitment of Pip to this site (lanes 4 and 5). Like PU.1, SPI-B is able to form a ternary complex with Pip (lanes 6 and 7) at this site, and the mutation S144A blocks the recruitment of Pip (lanes 8 and 9). Deletion of the entire PEST region of SPI-B
(ΔPEST) does not prevent DNA binding (lane 12) but does inhibit the recruitment of Pip to the site (lane 13).

Finally, two mutations that affect SPI-B DNA binding ability were tested for their ability to recruit Pip. First, the K242G mutation in SPI-B was found not to bind DNA by itself (lane 10), but a small amount of the ternary complex was formed when Pip was added (lane 11). This implies that a low affinity DNA-Pip interaction may be enough to allow the lower affinity K242G mutation to bind DNA. This type of mechanism has been observed with PU.1 and Pip at the CD20 promoter (16). However, a complete deletion of the Ets domain of SPI-B (ΔEts) prevents both DNA binding (lane 14) and formation of the ternary complex with Pip (lane 15).

Thus, while it appears that DNA binding and recruitment of Pip through a phosphorylated Ser-144 of SPI-B are important events for transactivation of the AB site, the mutation of any single Ser, Thr, or Tyr residue between aa 31 and 61 to alanine did not dramatically affect transactivation by SPI-B.

SPI-B Activity at the c-FES Promoter—To investigate the ability of SPI-B to transactivate a native promoter element that does not require Pip, a 450-base pair element derived from the c-FES promoter was tested. This promoter has been shown to require PU.1 (44) for maximal activity, as well as to be activated by SPI-B (21, 22). However, in our hands, SPI-B was unable to transactivate this promoter to the same levels as PU.1 (Fig. 5A). To test which domain(s) of SPI-B was responsible for this difference, a pair of chimeric molecules was generated where the PU.1 and SPI-B Ets domains were swapped. Thus, PU.1/SPI-B Ets is PU.1 with the SPI-B Ets domain, and SPI-B/PU.1 Ets is SPI-B with the PU.1 Ets domain. As demonstrated in Fig. 5A, the ability to transactivate this promoter segregated with the PU.1 Ets domain. This implies that either a difference in DNA binding or protein-protein interaction through the Ets domain of PU.1 are required for maximal activity of the c-FES promoter. Importantly, both the SPI-B/PU.1 Ets and PU.1/SPI-B Ets proteins efficiently transactivated the AB reporter plasmid (data not shown). These results are surprising because we assumed that the transcriptional activation domains of SPI-B, not its Ets domain, would prevent it from transactivating the c-FES promoter. To ensure that all constructs were capable of binding DNA, nuclear extracts from COS cells transfected with PU.1, SPI-B, and the two chimeric molecules were shown to contain proteins that bound to the AB site from the c-FES promoter (lanes 2–5). Furthermore, each protein could also be detected by Western blot assay at levels comparable to the positive control PU.1 (Fig. 3D, lanes 2, 3, 13, and 14).

To examine this further, equimolar amounts of IVT proteins were used in an EMSA (Fig. 5C) with oligonucleotides from both the AB site as well as the PU.1 site from the c-FES promoter (−11 to +11, 5′ TCAGGAACCTG 3′). All four proteins, PU.1, SPI-B, SPI-B/PU.1 Ets, and PU.1/SPI-B Ets, bound to the AB site efficiently (lanes 2–5) and interacted with Pip to form a ternary complex with DNA (lanes 6–10). However, only the PU.1 and SPI-B/PU.1 Ets constructs were able to efficiently bind to the c-FES site (lanes 12–15). By calculating binding constants for PU.1 and SPI-B at the AB and c-FES sites, PU.1 binds to the AB site 2-fold better than SPI-B but greater than 10-fold better to the c-FES site (data not shown). Together, these data indicate that although the SPI-B Ets domain seems to bind to the AB site, it binds at a much lower efficiency than PU.1 to the c-FES site. Therefore it appears that SPI-B has an overlapping but not identical DNA binding affinity to PU.1.

Protein-Protein Interactions of SPI-B and PU.1—PU.1 has been shown to interact with multiple proteins such as c-Jun (9), IRF family members (18), NF-IL6β (10), TBP (20), and other Ets proteins (8, 11, 12) to more potently activate transcription.
Fig. 6. GST affinity chromatography was utilized to explore which of the PU.1 interaction partners SPI-B could also bind. Full-length PU.1 and SPI-B cDNAs were fused to the C terminus of the GST protein, bound to glutathione-agarose beads, and tested for their ability to interact with \[^{35}S\text{methionine}\] IVT forms of Rb, TBP, NF-IL6β, c-Jun, PU.1, and SPI-B. Approximately equal counts of each IVT was used in each binding reaction; 1/10 the IVT used in each binding reaction was resolved by SDS-PAGE for comparison. IVT proteins were incubated with equal amounts (as judged by Coomassie stain) of bacterially expressed GST, GST-PU.1, or GST-SPI-B immobilized on glutathione-agarose beads, washed vigorously, eluted from the beads by boiling in loading dye, fractionated by SDS-PAGE, and visualized by autoradiography.

GST affinity chromatography was utilized to investigate the ability of \[^{35}S\text{methionine}\] IVT forms of Rb, TBP, NF-IL6β, c-Jun, PU.1, and SPI-B could interact with GST, GST-PU.1, or GST-SPI-B. Approximately equal counts of each IVT was used in each binding reaction; 1/10 the IVT used in each binding reaction was resolved by SDS-PAGE for comparison. IVT proteins were incubated with equal amounts (as judged by Coomassie stain) of bacterially expressed GST, GST-PU.1, or GST-SPI-B immobilized on glutathione-agarose beads, washed vigorously, eluted from the beads by boiling in loading dye, fractionated by SDS-PAGE, and visualized by autoradiography.}

Based upon these results, SPI-B is able to interact with similar protein partners as PU.1, although not with the same affinity in the case of NF-IL6β and Rb. However, we cannot rule out differences in interactions with other unknown cofactors that may contribute to the in vivo function of these two proteins.

**DISCUSSION**

We reasoned, based on the phenotypes of the PU.1\(^{−/−}\) and SPI-B\(^{−/−}\) mice, that differences in DNA-binding sites, transactivation domains, or interactions with cofactors would exist between PU.1 and SPI-B. To define better these structural and functional differences, we have delineated functional domains of SPI-B that allow it to activate transcription, as well as to investigate its interactions with known cofactors of PU.1. Initial studies based upon GAL4 fusion proteins and activation studies at a GAL4 DNA site have allowed us to map two independent activation domains in the N terminus of SPI-B. The first domain, located between amino acids 1 and 31, displays potent activation potential in the GAL4 system and represents a weakly acidic motif similar to that of PU.1 and most other Ets proteins (49) (see Fig. 7). Interestingly, this region is dispensable for the ability of SPI-B to transactivate the AB site of the lambda enhancer. In direct contrast, the second activation domain of SPI-B located between amino acids 41 and 61 as defined by the GAL4 system is essential for transactivation of the AB site. A similar example of transactivation domain selectivity has been observed for PU.1 at the J chain promoter in which the glutamine-rich region of PU.1 is required for maximal activity, but the acidic domains are dispensable (7). The important difference is that the transactivation domain required for SPI-B activity is a PST domain, a motif not observed in PU.1 or any other Ets family member (49). Although it is not surprising that SPI-B and PU.1 have different activation domains given the lack of similarity (only 20%) in the N terminus, it is unexpected that the two proteins contain activation domains containing widely divergent amino acids. Thus, differences in which genes are activated by PU.1 and SPI-B may rest upon which cofactors are recruited by a glutamine-rich versus PST domain.

To investigate further the ability of SPI-B to transactivate the AB DNA element, we explored the interactions of SPI-B with Pip at this element. First, like PU.1, SPI-B must bind to the DNA element and subsequently recruit Pip to the element. This recruitment, based upon our EMSA data, requires a phosphorylated Ser-144. Interestingly, our transfection data imply that whereas the PU.1 or SPI-B interaction via Ser-148/Ser-144 is important for maximal activity, it is not absolutely required as has been previously reported by some (13, 17, 18). The most likely explanation for these data is that the conditions of our transient transfections promote high level expression of the cDNA constructs and reporter, allowing lower affin-
ity interactions between SPI-B or PU.1 and Pip to compensate for the loss of phosphorylated Ser-144/Ser-148 at the interaction site, as reported by Brass et al. (18). These interactions are difficult to detect by EMSA because very small amounts of each IVT protein (~10 fmol) are used in each binding.

The inability of SPI-B to transactivate the myeloid c-FES promoter is perhaps most puzzling based upon the similarities in the Ets domain between PU.1 and SPI-B. Although it has been reported that PU.1 and SPI-B can transactivate this element (22), our data do not support this conclusion for SPI-B. One explanation is that Ray-Gallet et al. (22) observed lower transactivation (2-fold transactivation versus 12-fold from our data for PU.1) due to lower transfection efficiencies that may mask differences between constructs due to experimental error. Another explanation we cannot exclude is that the HeLa cells used by Ray-Gallet et al. (22) contained a cofactor required by the Ets domain of SPI-B for DNA binding and/or transcriptional activity at the c-FES promoter which is absent in our NIH 3T3 cells. Nonetheless, the evidence that SPI-B does not bind to the -11 to +11 PU.1 site in the c-FES promoter is surprising because multiple lines of evidence suggested that SPI-B had an identical DNA binding specificity to PU.1 in vitro (21, 23). However, based upon inspection of the 3′ flank of PU.1 and SPI-B consensus DNA-binding sites derived from site-selection experiments (22), the CTG contained in the 3′ flank of our c-FES-derived site (5′ TCAGGAACGT3′) does not appear in any of the sequences recovered for SPI-B but is recovered for PU.1. This implies that differences in the 3′ flank of the GGAA core of the PU.1/SPI-B DNA-binding site may determine the relative affinities of the two transcription factors for DNA. Based upon these differences in the 3′-flanking sequences, our data suggest that subtle differences in the α helix of the Ets domain may be responsible for differences in DNA binding affinity. This helix positions a critical arginine residue (Arg-173 in PU.1 and Arg-170 in SPI-B) involved in neutralization of the phosphate backbone 3′ to the GGAA core which allows DNA binding toward the recognition helix (51, 53, 54). Further analysis is required to ensure that the observed differences in DNA binding affinity between PU.1 and SPI-B is truly due to a difference in specificity. Nonetheless, analysis of divergent amino acids within this region of the PU.1 and SPI-B Ets domains may provide biochemical explanations for differences of DNA binding specificities of not just the PU.1 subfamily but other Ets proteins as well.

One proposed function of PU.1 is to act not only as a transcriptional activator but as a “scaffolding protein” which binds DNA and then allows other transcription factors to bind through protein-protein interactions, thereby creating an activation complex that recruits the basal transcription machinery to a promoter (33, 34, 55–57) for potent transcription. In fact, recent reports have shown that some or all of the activation domains of PU.1 are dispensable for transactivation, as long as other factors such as c-Jun, Pip, IκBZIP proteins, or other Ets proteins are also present (7, 12, 31, 55). Since these combinatorial-protein-protein interactions are important for proper tissue and temporal gene expression, we chose to examine the ability of SPI-B to interact with other proteins known to interact with PU.1. By using GST affinity chromatography, we have shown that SPI-B can interact with similar proteins to PU.1, although perhaps with lower affinity in the case of NF-IL6β and Rb. In addition, the ability of SPI-B to interact with TBP most likely allows it to transactivate the TATA-less c-FES promoter as long as it can bind to the promoter by using a PU.1 Ets domain. Thus, as with PU.1, SPI-B may transactivate TATA-less promoters in B lymphocytes by recruiting TBP and interact with other transcription factors to form an activation complex similar to PU.1.

Important differences in the transcriptional activation domains and DNA binding activity of SPI-B and PU.1 suggest that they have different target genes in vivo and therefore provide a framework to understand the non-redundancy presented by the PU.1−/− and Spi-B−/− animals. However, we cannot formally exclude the possibility that the genetic evidence of non-redundancy is due in part to post-translational modifications such as phosphorylation or interactions with currently unknown cofactors that might modulate the activity of PU.1 and SPI-B in vivo. Future experiments to understand the role of SPI-B as well as the different activation domains of PU.1 will provide important insights into not only the biology of these two proteins and how they are regulated but also how the interactions between different transactivation motifs can interact with the basal transcription machinery to cause gene expression.

Acknowledgments—We thank A. Brass and H. Singh for multiple vectors and thoughtful advice; M. Atchison for the NF-IL6 cDNA; and E. Morrisey and M. Parmacek for the pGAL4 and pGAL4-6G vectors. We thank L. Gottschalk, G. Schneider, and D. Wiler for expert preparation of the illustrations; Cheryl Small for secretarial assistance; and Donna Fackenthal for automated sequencing analysis. We also thank E. Morrisey, H. Ip, and T. McKeithan for critical review of the manuscript.

REFERENCES

1. Shvidrasani, R. A., and Orkin, S. H. (1996) Blood 87, 1025–4039
2. Orkin, S. H. (1995) Curr. Opin. Cell Biol. 7, 870–877
3. Macleod, K., Leprince, D., and Strehlow, D. (1992) Trends Biochem. Sci. 17, 251–256
4. Nye, J. A., Petersen, J. M., Gunther, C. V., Jonsen, M. D., and Graves, B. J. (1992) Genes Dev. 6, 975–990
5. Gunther, C. V., Nye, J. A., Bryner, R. S., and Graves, B. J. (1990) Genes Dev. 4, 667–679
6. Leprince, D., Cregieux, P., and Strehlow, D. (1992) Oncogene 7, 9–17
7. Shi, Y., and Kishland, M. E. (1993) Genes Dev. 7, 2006–2015
8. Basuayou, J. P., Ferreira, E., Strehlow, D., and Buttice, G. (1997) J. Biol. Chem. 272, 26188–26195
9. Bassuk, A. G., and Leiden, J. M. (1995) Immunity 3, 233–237
10. Nagalapalli, S., Pongubala, J. M., and Atchison, M. L. (1995) J. Immunol. 155, 4330–4338
11. Rao, E., Dang, W., Tian, G., and Sen, R. (1995) J. Biol. Chem. 270, 6722–6732
12. Erman, B., and Sen, R. (1996) EMBO J. 15, 4565–4575
13. Eisenbeis, C. F., Singh, H., and Storb, U. (1995) J. Immunol. 155, 11112–11123
14. Macleod, K., Leprince, D., and Strehlow, D. (1992) Trends Biochem. Sci. 17, 251–256
15. Klems, M. J., McKercher, S. R., Celada, A., Van Beveren, C., and Moreau-Gachelin, F. (1995) Oncogene 11, 303–313
16. Su, G. H., Ip, H. S., Cobb, B. S., Lu, M. M., Chen, H. M., and Simon, M. C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 1580–1584
17. Ottolenghi, E., and Orkin, S. H. (1993) Cell 74, 963–973
18. Klein, K., Celada, A., Van Beveren, C., and Moreau-Gachelin, F. (1995) Oncogene 11, 303–313
19. Zand, D. E., and Tenen, D. G. (1995) J. Biol. Chem. 270, 2623–2634
20. Brass, A. L., Krettl, E., Eisenbeis, C. F., Storb, U., and Singh, H. (1996) Genes Dev. 10, 2339–2347
21. Ray-Gallet, D., Ray-Gallet, D., Tavitian, A., and Moreau-Gachelin, F. (1992) Mol. Cell. Biol. 12, 4297–4304
22. Ray-Gallet, D., Lepage, E., and Tenen, D. G. (1992) Mol. Cell. Biol. 12, 113–124
Ezekowitz, R. A. (1997) *Blood* **90**, 4135–4143

35. Eisenbeis, C. F., Singh, H., and Storb, U. (1993) *Mol. Cell. Biol.* **13**, 6452–6461

36. Feldhaus, A. L., Mbarukhole, D., Arvin, K. L., Klug, C. A., and Singh, H. (1992) *Mol. Cell. Biol.* **12**, 1126–1133

37. Nelsen, B., Tian, G., Erman, B., Gregoire, J., Maki, R., Graves, B., and Sen, R. (1993) *Science* **261**, 82–86

38. Scott, E. W., Simon, M. C., Anastasi, J., and Singh, H. (1994) *Science* **265**, 1573–1577

39. Henkel, G. W., McKercher, S. R., Yamamoto, H., Anderson, K. L., Oshima, E. G., and Maki, R. A. (1996) *Blood* **88**, 2917–2926

40. McKercher, S. R., Torbett, B. E., Anderson, K. L., Henkel, G. W., Vestal, D. J., Baribault, H., Klemsz, M., Feeney, A. J., Wu, G. E., Paige, C. J., and Maki, R. A. (1996) *EMBO J.* **15**, 5647–5658

41. Anderson, K. L., Smith, K. A., Conners, K., McKercher, S. R., Maki, R. A., and Torbett, B. E. (1998) *Blood* **91**, 3702–3710

42. Scott, E. W., Fisher, R. C., Olson, M. C., Kehrl, E. W., Simon, M. C., and Singh, H. (1997) *Immunity* **6**, 437–447

43. Su, G. H., Chen, H., Muthususamy, N., Garrett-Sinha, L., Baunuch, D., Tenen, D. G., and Simon, M. C. (1997) *EMBO J.* **16**, 7118–7129

44. Heydemann, A., Juang, G., Hennessy, K., Parmacek, M. S., and Simon, M. C. (1996) *Mol. Cell. Biol.* **16**, 1676–1686

45. Morrissey, E. E., Ip, H. S., Tang, Z., and Parmacek, M. S. (1997) *J. Biol. Chem.* **272**, 8515–8524

46. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) *Gene (Amst.)* **77**, 51–59

47. Parmacek, M. S., Ip, H. S., Jung, F., Shen, T., Martin, J. F., Vora, A. J., Olson, E. N., and Leiden, J. M. (1994) *Mol. Cell. Biol.* **14**, 1870–1885

48. Andrews, N. C., and Faller, D. V. (1991) *Nucleic Acids Res.* **19**, 2499

49. Bassuk, A. G., and Leiden, J. M. (1997) *Adv. Immunol.* **64**, 65–104

50. Tang, H. K., Singh, S., and Saunders, G. F. (1998) *J. Biol. Chem.* **273**, 7210–7221

51. Kodandapani, R., Pio, F., Ni, C. Z., Piccialli, G., Klemsz, M., McKercher, S., Maki, R. A., and Ely, K. R. (1996) *Science* **273**, 456–460

52. Celada, A., Borras, F. E., Soler, C., Lloberas, J., Klemsz, M., van Beveren, C., McKercher, S., and Maki, R. A. (1996) *J. Exp. Med.* **184**, 61–69

53. Strauss-Soukup, J. K., and Maher, L. J., III (1997) *J. Biol. Chem.* **272**, 31570–31575

54. Pio, F., Kodandapani, R., Ni, C. Z., Shepard, W., Klemsz, M., McKercher, S. R., Maki, R. A., and Ely, K. R. (1996) *J. Biol. Chem.* **271**, 23329–23337

55. Pongubala, J. M., and Atchison, M. L. (1997) *Proc. Natl. Acad. Sci. U. S. A.* **94**, 127–132

56. Dang, W., Sun, X. H., and Sen, R. (1998) *Mol. Cell. Biol.* **18**, 1477–1488

57. Erman, B., Cortes, M., Nikolajczyk, B. S., Speck, N. A., and Sen, R. (1998) *Mol. Cell. Biol.* **18**, 1322–1330